Bayesian Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bayesian Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,800	Closed	-$1.13M	–	168
2025 Q3	$1.13M	Buy	20,800 +10,400	+100%	+$595K	0.23%	139
2025 Q2	$572K	Sell	10,400 -23,700	-70%	-$1.4M	0.09%	257
2025 Q1	$2.41M	Buy	34,100 +23,000	+207%	+$1.55M	0.4%	66
2024 Q4	$730K	Sell	11,100 -9,722	-47%	-$651K	0.09%	298
2024 Q3	$1.46M	Buy	+20,822	New	+$1.74M	0.17%	178
2023 Q1	–	Sell	-20,304	Closed	-$2.1M	–	794
2022 Q4	$2.1M	Buy	+20,304	New	+$1.91M	0.31%	59
2021 Q1	–	Sell	-2,419	Closed	-$212K	–	540
2020 Q4	$212K	Sell	2,419 -401	-14%	-$31.8K	0.06%	371
2020 Q3	$215K	Buy	+2,820	New	+$285K	0.05%	428
2017 Q3	–	Sell	-5,200	Closed	-$472K	–	482
2017 Q2	$472K	Buy	+5,200	New	+$473K	0.17%	196

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bayesian Capital Management's BMRN Position: Q4 2025 in Review

Bayesian Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 20,800 shares — an estimated $1.13M sold.

Bayesian Capital Management first reported a position in BMRN in Q2 2017 and held it in 9 quarters. The position peaked at $2.41M in Q1 2025. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Bayesian Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Bayesian Capital Management sold 20,800 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.13M.
Bayesian Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2017 and held it in 9 quarters.
Bayesian Capital Management's BioMarin Pharmaceuticals position peaked at $2.41M in Q1 2025.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.